Hainan Huluwa Pharmaceutical Group News

Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.

00:00

Legal Opinion of Beijing Guofeng Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.

00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the progress of capital increase for wholly-owned subsidiaries through debt-for-share swaps

Nov 23 00:00

Meeting materials of the 2024 Second Extraordinary General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.

Nov 15 00:00

Notice of Hainan Huluwa Pharmaceutical Group Co., Ltd. on convening the 2nd Extraordinary General Meeting of Shareholders in 2024

Nov 12 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on changing some fund-raising investment projects

Nov 12 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on by-election of independent directors

Nov 12 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the receipt of GMP compliance test results by its wholly-owned subsidiary

Nov 6 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the resignation of an independent director at the end of their term of office

Oct 30 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on increasing the capital of wholly-owned subsidiaries through debt-for-share swaps

Oct 19 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on providing guarantees for wholly-owned subsidiaries

Oct 17 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on providing guarantees for wholly-owned subsidiaries

Oct 1 00:00

Hainan Huluwa Pharmaceutical Group Co., Ltd. received the Shanghai Stock Exchange\'s “Decision on Termination of the Review of Hainan Huluwa Pharmaceutical Group Co., Ltd.\'s Issuance of Convertible Corporate Bonds to Unspecified Targets”

Sep 9 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the wholly-owned subsidiary obtaining a drug registration certificate for lacosamide oral solution

Aug 28 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on issuing convertible corporate bonds to unspecified targets on the results of the review meeting of the Shanghai Stock Exchange Listing Review Committee

Aug 27 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. about its wholly-owned subsidiary obtaining the registration certificate for ibuprofen suspension drip pharmaceutical.

Aug 7 00:00

Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the compliance inspection results of pharmaceutical GMP received by its wholly-owned subsidiary.

Aug 7 00:00

Legal Opinion of the 2023 Annual General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.

May 23 00:00

Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.

May 23 00:00

Response to the implementation letter of the opinions of the Listing Review Committee Meeting of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the issuance of convertible corporate bonds to unspecified targets

May 21 00:00